Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
Authors
Keywords
-
Journal
Biosensors-Basel
Volume 12, Issue 8, Pages 617
Publisher
MDPI AG
Online
2022-08-09
DOI
10.3390/bios12080617
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dostarlimab for the treatment of advanced endometrial cancer
- (2022) Andres Redondo et al. Expert Review of Clinical Pharmacology
- Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
- (2022) Ana Oaknin et al. Journal for ImmunoTherapy of Cancer
- Safety and Efficacy of Dostarlimab in Patients with Recurrent/Advanced Non-Small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial
- (2022) Victor Moreno et al. Clinical Lung Cancer
- Folic acid conjugated poly(amidoamine) dendrimer as a smart nanocarriers for tracing, imaging, and treating cancers over-expressing folate receptors
- (2022) Mahak Fatima et al. EUROPEAN POLYMER JOURNAL
- Computational Identification of Druggable Bioactive Compounds from Catharanthus roseus and Avicennia marina against Colorectal Cancer by Targeting Thymidylate Synthase
- (2022) Md Rashedul Islam et al. MOLECULES
- Curcumin-based nanotechnology approaches and therapeutics in restoration of autoimmune diseases
- (2022) Niloufar Rahiman et al. JOURNAL OF CONTROLLED RELEASE
- PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
- (2022) Andrea Cercek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment
- (2022) Ravi Bandaru et al. PROCESS BIOCHEMISTRY
- Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.
- (2021) Thierry Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer
- (2021) Sima Singh et al. DRUG DISCOVERY TODAY
- Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy
- (2021) Zahid Hussain et al. JOURNAL OF CONTROLLED RELEASE
- An Integrated Analysis of Dostarlimab Immunogenicity
- (2021) Sharon Lu et al. AAPS Journal
- Dostarlimab: First Approval
- (2021) Anthony Markham DRUGS
- Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study.
- (2021) Dominique Berton et al. JOURNAL OF CLINICAL ONCOLOGY
- A prospective phase II single arm study of niraparib plus dostarlimab in patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germline or somatic mutations in the DNA repair genes: Rationale and Study design
- (2020) Francesco Passiglia et al. Clinical Lung Cancer
- Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care
- (2020) Sima Singh et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- 880TiP Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study
- (2020) A. Oaknin et al. ANNALS OF ONCOLOGY
- Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
- (2020) Ana Oaknin et al. JAMA Oncology
- Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer
- (2020) Lawrence Kasherman et al. Future Oncology
- Advances in cancer immunotherapy 2019 – latest trends
- (2019) Stephan Kruger et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Immune checkpoint inhibitors: a promising anticancer therapy
- (2019) Sima Singh et al. DRUG DISCOVERY TODAY
- Immune checkpoint inhibitors win the 2018 Nobel Prize
- (2019) Pei-Wei Huang et al. Biomedical Journal
- Hyaluronic acid decorated tacrolimus-loaded nanoparticles: Efficient approach to maximize dermal targeting and anti-dermatitis efficacy
- (2018) Fan Zhuo et al. CARBOHYDRATE POLYMERS
- Design and development of novel hyaluronate-modified nanoparticles for combo-delivery of curcumin and alendronate: fabrication, characterization, and cellular and molecular evidences of enhanced bone regeneration
- (2018) Jinlei Dong et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Self-assembled biodegradable polymeric micelles to improve dapoxetine delivery across the blood–brain barrier
- (2018) Mohammed Abourehab et al. International Journal of Nanomedicine
- Identification and characterization of a novel antimicrobial peptide compound produced by Bacillus megaterium strain isolated from oral microflora
- (2018) Abdullah S.A. Al-Thubiani et al. SAUDI PHARMACEUTICAL JOURNAL
- Monoclonal antibodies in cancer immunotherapy
- (2018) Ilgin Kimiz-Gebologlu et al. MOLECULAR BIOLOGY REPORTS
- Bilosomes in the context of oral immunization: development, challenges and opportunities
- (2016) Anshuman Shukla et al. DRUG DISCOVERY TODAY
- Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis: A Randomized Clinical Trial
- (2011) S. Swaminathan et al. CLINICAL INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started